Needham Cuts Artiva Biotherapeutics to Hold From Buy
Needham lowered its rating on Artiva Biotherapeutics shares from Buy to Hold, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Dow Jones Newswires reported that Needham downgraded its rating on Artiva Biotherapeutics (ARTV) shares from Buy to Hold. The information comes from a ratings roundup published by Benzinga.
why it matters
Downgrades by individual analysts usually affect sentiment around a single stock, but they rarely change the picture for the broader market. The event is local and concerns one company.
tags
instruments
sources
- Artiva Biotherapeutics Cut to Hold From Buy by Needham — Dow Jones Newswires, 27 October 2026 at 17:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗